share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  09/30 20:03

牛牛AI助理已提取核心訊息

On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
On September 30, 2024, Novo Nordisk A/S, a leading global healthcare company, reported progress on its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific tranche was initiated on August 7, 2024, with the intention to repurchase up to DKK 2.4 billion in B shares by November 4, 2024. Since the last announcement on September 23, 2024, Novo Nordisk has purchased an additional 205,935 B shares at an average price of DKK 835.48, amounting to DKK 172,706,664. This brings the total repurchased under the program to 1,604,058 B shares at an average price of DKK 880.84, totaling DKK 11,161,264,179. The company now holds 13,999,815 B shares as treasury shares, representing 0.3% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and employs approximately 69,000 people worldwide.
2024年9月30日，全球領先的醫藥公司諾和諾德（Novo Nordisk A/S）報告了其股份回購計劃的進展。該計劃始於2024年2月6日，旨在在12個月內以高達200億丹麥克朗的價格回購股份。作爲該倡議的一部分，於2024年8月7日啓動了一項特定的交易，計劃到2024年11月4日前回購約24億丹麥克朗的b股。自2024年9月23日最後一份公告以來，諾和諾德以平均每股835.48丹麥克朗的價格，額外購買了2059350億股，總價值爲172,706,664丹麥克朗。這使得在該計劃下累計回購的股份總數達到16040580億股，平均每股880.84丹麥克朗，總計11,161,264,179丹麥克朗。該公司目前持有139998150億股作爲庫存股，佔股本的0.3％。成立於1923年，總部位於丹麥的諾和諾德致力於對抗嚴重慢性疾病，全球約有69,000名員工。
2024年9月30日，全球領先的醫藥公司諾和諾德（Novo Nordisk A/S）報告了其股份回購計劃的進展。該計劃始於2024年2月6日，旨在在12個月內以高達200億丹麥克朗的價格回購股份。作爲該倡議的一部分，於2024年8月7日啓動了一項特定的交易，計劃到2024年11月4日前回購約24億丹麥克朗的b股。自2024年9月23日最後一份公告以來，諾和諾德以平均每股835.48丹麥克朗的價格，額外購買了2059350億股，總價值爲172,706,664丹麥克朗。這使得在該計劃下累計回購的股份總數達到16040580億股，平均每股880.84丹麥克朗，總計11,161,264,179丹麥克朗。該公司目前持有139998150億股作爲庫存股，佔股本的0.3％。成立於1923年，總部位於丹麥的諾和諾德致力於對抗嚴重慢性疾病，全球約有69,000名員工。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間